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Age-dependent neurodegeneration and
Alzheimer-amyloid plaque formation in transgenic
Drosophila
Abstract
Beta-amyloid peptides that are cleaved from the amyloid precursor protein (APP) play a
critical role in Alzheimer's disease (AD) pathophysiology. Here, we show that in Drosophila,
the targeted expression of the key genes of AD, APP, the beta-site APP-cleaving enzyme
BACE, and the presenilins led to the generation of beta-amyloid plaques and age-dependent
neurodegeneration as well as to semilethality, a shortened life span, and defects in wing vein
development. Genetic manipulations or pharmacological treatments with secretase inhibitors
influenced the activity of the APP-processing proteases and modulated the severity of the
phenotypes. This invertebrate model of amyloid plaque pathology demonstrates
Abeta-induced neurodegeneration as a basic biological principle and may allow additional
genetic analyses of the underlying molecular pathways.
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-Amyloid peptides that are cleaved from the amyloid precursor protein (APP) play a critical role in Alzheimer’s disease (AD) patho-
physiology. Here, we show that in Drosophila, the targeted expression of the key genes of AD, APP, the-site APP-cleaving enzyme BACE,
and the presenilins led to the generation of -amyloid plaques and age-dependent neurodegeneration as well as to semilethality, a
shortened life span, and defects in wing vein development. Genetic manipulations or pharmacological treatments with secretase inhib-
itors influenced the activity of the APP-processing proteases and modulated the severity of the phenotypes. This invertebrate model of
amyloid plaque pathology demonstrates A-induced neurodegeneration as a basic biological principle and may allow additional genetic
analyses of the underlying molecular pathways.
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Introduction
Alzheimer’s disease (AD) neuropathology is characterized by the
accumulation and deposition of -amyloid (A) peptides in se-
nile plaques, by the formation of neurofibrillary tangles (NFT)
composed of abnormally phosphorylated forms of the microtu-
bule binding protein tau, and by a progressive neuronal damage
and cell loss (Gomez-Isla et al., 1996; Selkoe, 1999). The interre-
lation of A and NFT in the development of AD neuropathologic
lesions is a matter of debate. However, it has been shown that in
AD-linked neurodegeneration, A is an essential causative
pathogenic factor. Tau-related neurotoxicity was recapitulated in
transgenic Drosophila, demonstrating that important aspects of
AD-related neuropathogenesis can be studied in the fruit fly
(Wittmann et al., 2001; Jackson et al., 2002). A-induced neuro-
degeneration and plaque formation in Drosophila would provide
powerful additional evidence for a causative role of A peptide
toxicity in AD.
A is generated by endoproteolysis of the amyloid precursor
protein (APP) by -secretase activity of the -site APP-cleaving
enzyme (BACE) and by subsequent intramembraneous
-secretase cleavage that depends on a complex of presenilin 1 or
2 (PS1 or PS2), nicastrin, aph-1, and pen-2 (De Strooper and
Annaert, 2000; Walter et al., 2001; Esler et al., 2002; Francis et al.,
2002). Autosomal dominant mutations in APP, PS1, or PS2 ac-
celerate the onset of neurodegeneration and the progression of
the disease in familial AD (FAD). These FAD mutations are asso-
ciated with altered APP processing and lead to an increased gen-
eration of amyloidogenic A40 and A42 peptides or to increased
ratios of A42/Atotal (Lemere et al., 1996; Scheuner et al., 1996;
Tomita et al., 1997). Previous studies of Drosophila suggested
pro-apoptotic functions of FAD-causing presenilin mutations
and indicated that, although the genes required for a functional
-secretase complex appeared to be highly conserved between
Drosophila and vertebrates, the fly is lacking a homolog of human
BACE (Fossgreen et al., 1998; Ye and Fortini, 1999; Adams et al.,
2000).
To model -amyloid plaque pathology and neurodegenera-
tion in Drosophila, we expressed the genes involved in the patho-
physiology of AD either separately or in combination in various
neuronal and non-neuronal tissues by using the GAL4/UAS
(transcriptional activator Gal4/Gal4 DNA binding motif, up-
stream activator sequence) system (Brand and Perrimon, 1993).
Transgenic flies expressing the human APP695 gene (UAS-APP)
and three fly lines expressing Drosophila presenilin (UAS-DPsn)
point mutations that correspond to the FAD mutants N141I,
L235P, and E280A were kindly provided by R. Paro (Center for
Molecular Biology, Heidelberg, Germany) and E. Fortini (Na-
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tional Cancer Institute, Molecular Genetics Section, Frederick,
MD), respectively (Fossgreen et al., 1998; Ye and Fortini, 1999).
We generated UAS-BACE transgenic fly lines by P-element-
mediated germline transformation and expressed APP, BACE,
and DPsn in photoreceptor cells of the compound eye of Dro-
sophila by using the eye-specific gmr-GAL4 driver line (Rubin
and Spradling, 1982; Spradling and Rubin, 1982; Brand and Per-
rimon, 1993).
Materials and Methods
BACE transgenic flies. A 1.9 kb KpnI-XhoI restriction fragment of the
human BACE (-site APP-cleaving enzyme) cDNA containing the entire
open reading frame was cloned into the plasmid pUAST (Brand and
Perrimon, 1993). P-element-mediated germline transformation was per-
formed as described (Rubin and Spradling, 1982; Spradling and Rubin,
1982). Three independent UAS-BACE insertion lines were used in our
experiments (406, 437, 523).
APP and presenilin transgenic flies. The UAS-APP695II, UAS-
APP695III (Wt-34, Wt-35) and the UAS-DPsn14 as well as UAS-
DPsn-mutants (N141I, L235P, E280A) were kindly provided by R. Paro
and E. Fortini (Fossgreen et al., 1998; Ye and Fortini, 1999). PsnC4,
psnB3, and the psnK2 mutant alleles as well as the actin-GAL4 line were
obtained from the Bloomington stock center. The gmr-GAL4 line from
F. Pignoni was used to achieve the eye-specific expression of the
transgenes.
Protein analyses. For Western blotting, fly heads and human normal
brain tissue (Alzheimer Tissue Center, Northwestern University, Evan-
ston, IL; A97–197 ITC; PMI 5 hr) were homogenized in 1 PBS, 5 mM
EDTA, 0.5% Triton X-100, and a protease-inhibitor mix Complete
(Roche Applied Science, Mannheim, Germany). Equal amounts of pro-
tein were separated by 10% SDS-PAGE, transferred to Immobilon mem-
branes (Millipore, Bedford, MA), blocked in 5% low-fat milk for 2 hr at
room temperature, and incubated with the monoclonal antibody (mAb)
22C11 (APP N terminal-specific; Chemicon, Temecula, CA) or poly-
clonal Ab (pAb) -APP-C12 (APP C terminal-specific; kind gift from B.
de Strooper, Center for Human Genetics, K.U. Leuven and Flanders
Interuniversity Institute for Biotechnology, Leuven, Belgium). Bound
antibodies were detected with goat anti-mouse peroxidase-conjugated
(Dianova, Hamburg, Germany) or goat anti-rabbit peroxidase-
conjugated (Vector Laboratories, Burlingame, CA) secondary antibod-
ies. For immunoprecipitation, fly heads were homogenized as described
above, and lysates were treated as described in the antibodies protocol
guide from Clontech (Cambridge, UK). The following antibodies were
used for immunoprecipitation: mAb 6E10 (-A5–10; Signet Pathology
Systems, Dedham, MA), mAb 4G8 (-A17–24; Signet Pathology Sys-
tems), rabbit pAb-APP-C12, and rabbit polyclonal antibodies A1– 42
and A1– 40 (QCB; Biosource International, Camarillo, CA). Samples
were separated on 10 –20% gradient Novex (Wadsworth, OH) Tris-
Tricine gels (Invitrogen, San Diego, CA) and blotted onto Protran BA 79
Cellulosenitrate membranes (0.1 m; Schleicher & Schuell, Dassel, Ger-
many). Detection of -amyloid or the APP C terminus was performed as
described previously (Ida et al., 1996) using mAb 6E10 and goat anti-
mouse peroxidase-conjugated secondary Ab (Dianova).
Immunohistochemistry and histology. For Immunostaining, adult flies
were fixed in 4% paraformaldehyde for 3 hr, washed in 1 PBS, and
transferred to 25% sucrose for an overnight incubation at 4°C. Flies were
decapitated with a razor blade, and the heads were imbedded in Tissue
Tek (Sakura, Tokyo, Japan) and snap frozen. Horizontal frozen sections
(10m) were prepared on a cryostat. Immunostaining was done with the
Vectastain Elite kit (Vector Laboratories) according to the instructions of
the manufacturer. The following primary antibodies were used: 24B10
(-chaoptin, 1:5), provided by the Developmental Studies Hybridoma
Bank; mAb 4G8 (1:1000), and mAb 9G10 (A42 C terminus that was
generated by standard procedures; 1:500). The fly brain tissue sections
were pretreated for 10 min in 70% formic acid to re-expose the epitope
before 4G8 staining.
For thioflavin S staining, sections were counterstained for 5 min in
Mayers Hemalum (Sigma, St. Louis, MO), rinsed for 10 min in tap water,
and stained for 3 min in 1% thioflavin S (Sigma) watery solution. Slides
were rinsed in several changes of distilled water, incubated for 15 min in
1% acetic acid, rinsed in tap water, and mounted in Vectashield mount-
ing medium (Vector Laboratories). Slides were analyzed under a fluores-
cence microscopy (430 nm excitation, 550 nm emission).
For plastic sections, flies were fixed overnight in 5% glutaraldehyde at
4°C, decapitated with a razor blade, washed three times in PBS (5 min
each), and treated with 2% osmium-tetraoxid on ice. Sections were again
washed three times for 10 min each, sequentially dehydrated in 50, 70, 80,
95, and 3 100% ethanol for 10 min each, incubated in 100% ethanol:
epon 1:1 overnight, and embedded in epon. Plastic sections (1m) were
cut on a microtome and stained with 1% toluidine blue, 1% borax.
Ultra-thin sections (60 nm) were stained with aqueous uranyl acetate and
lead citrate and examined using a CEM 902A (Zeiss, Thornwood, NY)
electron microscope and analySIS software (SIS, Mu¨nster, Germany).
Adult fly wings were removed and mounted in DPX (a mixture of disty-
rene, tricresyl phosphate, and xylene) mountant (Fluka, Buchs, Switzer-
land) for light microscopy.
Treatments with - and - secretase inhibitors. The -secretase inhibi-
tor (Sinha et al., 1999) (Calbiochem, La Jolla, CA; 171601) or the
-secretase inhibitor (Dovey et al., 2001) (Calbiochem; 565770) were
used for treatment. The -secretase inhibitor was added to the standard
fly medium to a final concentration of 1, 5, 10, 20, and 50 nM in 0.001,
0.005, 0.01, 0.02, and 0.05% DMSO, respectively; for the -secretase
inhibitor, a final concentration of 100 nM in 0.001% DMSO was used.
Flies of the following genotypes were mated: w;actin-GAL4/Cyo;UAS-
DPsn/Tm3 x w;UAS-APP/UAS-APP;UAS-BACE/UAS-BACE. The eggs
were developed on fly medium supplemented with the inhibitors or with
the vehicle (DMSO) through the larval stage until eclosion. The eclosion
rate and extra vein phenotype of flies transgenic for w;actin-GAL4/UAS-
APP;UAS-BACE523/UAS-DPsn, w;actin-GAL4/UAS-APP;UAS-BACE406/
UAS-DPsn, and w;actin-GAL4/;UAS-DPsn/ were scored. Adult trans-
genic flies were continuously treated at 29°C with or without 10 nM
-secretase inhibitor in 0.01% DMSO supplied with the fly food.
Results
Amyloidogenic processing of human APP in transgenic flies
In UAS-APP-expressing flies, antibodies against the N or C ter-
mini of human APP detected two differently glycosylated full-
length forms of APP that comigrated with glycosylated APP695
from human brain tissue at 100 kDa (Fig. 1A, lanes 1, 3, 5).
Transgenic coexpression of human BACE with APP resulted in
the loss of higher glycosylated APP, together with the generation
of a smaller 97 kDa N-terminal fragment that corresponded in
molecular mass to the -cleaved secreted ectodomain of APP
(APPs) (Fig. 1A, lanes 2, 4). Thus, in Drosophila, human BACE
appeared to cleave preferentially the higher glycosylated form of
APP. In SDS protein extracts from double-transgenic flies, the
monoclonal anti-A Ab 6E10 (-A1–16) precipitated the
-cleaved C terminus of APP [-C-terminal fragment (CTF)]
(Fig. 1C) as well as SDS-stable A dimers and oligomers (Fig. 1B,
lane 3, rhomb). Flies transgenic for UAS-APP without BACE
generated a slightly larger form of A, -A (-cleaved A) (Fig.
1B, lane 4, asterisk). Like A, -A also formed SDS-stable
dimers and oligomers. Identical bands were generated by immu-
noprecipitation with the mAb 4G8 (-A17–24) or with poly-
clonal A40 or A42 C terminal-specific antibodies that recognize
only the free C terminus of A40 or A42, respectively (data not
shown). A and -Awere absent from nontransgenic w 1118 flies
and BACE transgenic flies (Fig. 1B, lanes 2, 9, 13) and were hardly
detectable when only low levels of APP were expressed by the
weak nervous system-specific elav-GAL4 line (Fig. 1B, lanes 5, 6).
After extraction of fly proteins in the presence of 70% formic
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acid, A immunoprecipitated from UAS-APP/UAS-BACE trans-
genic flies comigrated exactly with the size of the synthetic A (4
kDa), whereas -A from UAS-APP transgenic flies migrated
with a slightly larger molecular mass (5 kDa) (Fig. 1B, right
panel, rhombs and asterisk, respectively). Notably, in the pres-
ence of 70% formic acid, a-CTF was immunoprecipitated from
UAS-APP/UAS-BACE transgenic flies, whereas a -CTF could
hardly be detected under these conditions in UAS-APP trans-
genic flies (Fig. 1B, lanes 10 –12).
To further characterize the -secretase processing of APP
in Drosophila in the absence of BACE, we immunoprecipitated
the C terminus of APP with mAb 6E10
and used a pAb against the last 12
C-terminal amino acids of full-length
APP for detection on Western blots
(Selkoe et al., 1988). In UAS-APP flies,
6E10 precipitated an APP C-terminal
fragment with an apparent molecular mass
of 13 kDa (-CTF), as compared with the
expected 11 kDa -CTF in UAS-APP/UAS-
BACE-expressing flies (Fig. 1C).
Age-dependent neurodegeneration of
photoreceptor cells in
transgenic Drosophila
The neuropathology associated with amy-
loidogenic APP processing was character-
ized in the compound eye of Drosophila by
staining cryostat sections with the photo-
receptor cell-specific mAb 24B10. At day 2
after eclosion, no structural differences be-
tween UAS-BACE and UAS-APP single or
UAS-APP/UAS-BACE double transgenic
flies could be detected (Fig. 2A). At day 18,
however, a severe degeneration of the ret-
inal photoreceptors and their axonal pro-
jections to the first and second optic gan-
glion, in particular the lamina, was observed
in UAS-APP/UAS-BACE transgenic flies
(Fig. 2A). This degeneration of retinal pho-
toreceptors was more pronounced in UAS-
APP transgenic flies, but completely absent
in UAS-BACE-expressing control flies (Fig.
2A). At day 30, the neurodegeneration had
progressed further as indicated by small de-
generated retinas and a reduced volume of
the underlying optic neuropil, the lamina. In
addition, the photoreceptor cell projections
to the medulla were heavily degenerated and
stained only weakly.
Degeneration of photoreceptor cells is
dependent on -secretase activity
The -secretase activity of the flies was
modulated by coexpressing the Drosophila
FAD-presenilin genes or by introducing
loss of function alleles of the endogenous
presenilin gene that reduces -secretase
processing. Presenilin loss of function mu-
tations psnC4, psnK2, psnB3, or one of
three different human FAD mutants UAS-
DPsnN141I, E280A, or L235P (Ye and
Fortini, 1999; Ye et al., 1999) were ex-
pressed in w; UAS-APP/; gmr-GAL4/ transgenic background.
At 12 d of age, the heterozygous presenilin loss of function mu-
tants (w; UAS-APP/; gmr-GAL4/psnB3) suppressed the de-
generation of photoreceptor cells of UAS-APP-expressing flies,
whereas coexpression of the presenilin FAD mutant L235P (w; UAS-
APP/; gmr-GAL4/UAS-DPsnL235P) enhanced the degeneration
(Fig. 2B). Similar results were obtained with two additional loss-of-
function presenilin mutations psnK2 and psnC4 and with the FAD
mutants UAS-DPsnN141I and UAS-DPsnE280A, and also when
BACE was coexpressed (data not shown).
Figure 1. Amyloidogenic processing of APP in Drosophila. A, Equal amounts of protein extracts from transgenic flies at 2 d after
eclosion were analyzed by Western blots, and full-length APP (fl-APP) was detected with APP-N-terminal (top panel) and APP-
C-terminal (bottom panel) antibodies. Human brain extracts from the inferior temporal lobe (ITC) region were analyzed in parallel
as control. B, Immunoprecipitation and immunoblotting of A (rhomb) and the alternatively -cleaved -A (asterisk) from
extracts of transgenic and nontransgenic w 1118 flies at 2 d after eclosion with and without the addition of synthetic A1– 40 using
the A-specific mAb 6E10. Fly proteins were extracted in SDS (left panel) or in 70% formic acid (right panel). C, Immunoprecipi-
tation of the APP-C terminus by mAb 6E10 and detection by Western blotting with anti-APP-C12. D, Schematic representation of
the amyloidogenic processing of APP at the secretase-cleavage sites. The amino acid sequence of the presumptive-A peptide
is indicated. The -secretase processing site was deduced from -secretase-processed APP695 found in rat primary neurons. A
sequence is indicated in bold letters. The epitopes of the antibodies that were used to characterize APP processing in transgenic
flies are indicated by black bars.
Greeve et al. •-Amyloid-Induced Neurodegeneration in Drosophila J. Neurosci., April 21, 2004 • 24(16):3899 –3906 • 3901
-amyloid staining of plaques in the retina of
transgenic Drosophila
Cryostat sections through eyes and optic lobes of adult double or
single transgenic flies with accelerated degeneration of photore-
ceptor cells were stained with either thioflavin S or the
-amyloid-detecting mAb 4G8. Both thioflavin S and mAb 4G8
detected large globular deposits in the retinas of UAS-APP/UAS-
DPsnL235P or UAS-APP/UAS-BACE/UAS-DPsnL235P flies
(Fig. 3A–D). These large globular deposits also could be stained
with the C-terminal end-specific A-42 mAb 9G10 (data not
shown). The deposits occurred age dependently with an onset at
day 37 after eclosion in UAS-APP/UAS-DPsnL235P and UAS-
APP/UAS-BACE/UAS-DPsnL235P flies (Fig. 3J). In UAS-APP
and in UAS-APP/UAS-BACE transgenic flies without additional
DPsnL235P, the onset of plaque formation was strongly delayed
and did not occur before day 68 after eclosion (Fig. 3J). In all of
these fly lines, the neuronal degeneration preceded the occur-
rence of the amyloid plaques (Fig. 3J). Electron microscopy de-
tected many “star-like” deposits of various sizes in the retina
and neuropil regions of the first and second optic ganglion in
UAS-APP/UAS-DPsnL235P and UAS-APP/UAS-BACE/UAS-
DPsnL235P flies (Fig. 3E–H ). These star-like deposits resem-
bled the fibrillar EM ultrastructure of -amyloid plaques in
brains of human AD patients or APP-transgenic mice (Rock-
enstein et al., 2001) and were only found in EM sections of flies
containing thioflavin S-positive plaques but not in flies without
thioflavin S-positive plaques. The -amyloid plaques that are
formed by the deposition of either A or -A in UAS-APP/
UAS-BACE/UAS-DPsnL235P or UAS-APP/UAS-DPsnL235P
flies, respectively, shared a similar if not identical ultrastructure
(Fig. 3G,H).
Ubiquitous expression of APP, BACE, and Presenilin
Next, APP, BACE, and an additional copy of the DPsn gene were
expressed ubiquitously in neuronal and non-neuronal cells of the
fly by using actin-GAL4. Flies expressing APP alone or in combi-
nation with BACE and DPsn under the control of actin-GAL4
demonstrated semilethality and ectopic wing vein formation (Ta-
ble 1, lines 3, 4; Fig. 4B–D, arrows). Only the UAS-DPsn and
UAS-BACE/UAS-DPsn-expressing flies showed a normal sur-
vival rate and presented the correct wing vein pattern consisting
of five longitudinal veins (L1–L5) and two cross veins [anterior
and posterior cross veins (CVs)] (Fig. 4A; Table 1, lines 1, 2).
Both the reduced viability and the wing vein phenotype were
aggravated by the introduction of an additional presenilin copy,
and they were rescued by presenilin loss of function mutations
( psnC4) (Table 1, lines 4, 5; Fig. 4C,D). Replacing the human
APP by its Drosophila homolog APPL, which does not contain an
A domain, rescued the lethality completely (Table 1, line 7),
which implies an A-related toxicity mechanism.
- and -secretase inhibitors to modulate A formation
To determine whether these phenotypes are suitable for the val-
idation of therapeutic drugs designed to reduce A formation,
the fly larvae were kept on a special fly medium supplemented
either with BACE inhibitors or -secretase inhibitors (Sinha et
al., 1999; Dovey et al., 2001). The eclosion rates of transgenic
larvae that were raised on nonsupplemented medium and on
medium supplemented with the respective inhibitors or the ve-
hicle only were evaluated. Treatment of Act-GAL4;UAS-APP/;
UAS-BACE/UAS-DPsn larvae with the BACE inhibitor at con-
centrations ranging from 1 to 50 nM increased the survival rates in
a dose-dependent manner with a maximum effectiveness at 10
nM. Although 1 nM BACE inhibitor had no effect on the survival
rate of transgenic flies, 10 nM BACE inhibitor increased the sur-
vival rate by a factor of 3 (0.17 vs 0.06) (Table 1, line 8). In other
words, the ratio of eclosed flies expressing the transgenes of in-
terest to the total number of flies eclosed was 1:18 (0.06) in the
group of larvae raised on the vehicle-supplemented food and 1:6
(0.17) in the 10 nM BACE inhibitor-treated group.
Prolonged treatment of adult flies with the BACE inhibitor
markedly increased their life expectancy from 13 to 20 d in com-
parison with the vehicle-treated control flies (Fig. 5, gray and
Figure 2. Age-dependent neurodegeneration in flies expressing the AD-associated trans-
genes under the control of the eye-specific gmr-GAL4 line. A, Staining of the photoreceptors in
the retina (re) and their axonal projections to the lamina (la) and the medulla (me) on cryostat
sections of different transgenic fly lines at days 2, 18, and 30. Photoreceptor degeneration in w;
UAS-APP/; gmr-GAL4/and w; UAS-APP/; gmr-GAL4/UAS-BACE transgenic flies but not in
w; gmr-GAL4/UAS-BACE transgenic control flies depends on age. The observed age-dependent
degeneration of photoreceptor cells was not gender specific. B, Photoreceptor staining of trans-
genic flies at day 12. Loss of presenilin function in the w; UAS-APP/; gmr-GAL4/psnB3 flies
rescues the neurodegeneration; gain of presenilin function in w; UAS-APP/; gmr-GAL4/UAS-
DPsnL235P transgenic flies aggravates the phenotype. Scale bars: A, 45m; B, 50m.
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black triangles). Treatment of flies that do not express APP but
only an additional copy of the Drosophila presenilin gene with
either BACE inhibitor or vehicle did not alter their life span (Fig.
5, gray and black dots). Treatment of transgenic fly larvae with
the -secretase inhibitor at a concentration of 100 nM increased
their survival rates by a factor of 4.5 [ratio of inhibitor-treated
flies, 1:22 (0.045), vs ratio of vehicle-treated flies, 1:97 (0.01)]
(Table 1, line 9). The eclosion rates of Act-GAL4;UAS-DPsn/
control flies were consistently at 0.33 and were not influenced by
either the vehicle or inhibitor (Table 1, line 10). In addition,
BACE inhibitor treatment reduced the ectopic wing vein pheno-
type in Act-GAL4;UAS-APP/;UAS-BACE/UAS-DPsn trans-
genic flies, underscoring that it was related to aberrant APP pro-
cessing during development.
Discussion
Here, we describe the generation of a Dro-
sophila model for AD-related-amyloidosis
and neurodegeneration that is based on
the accumulation and deposition of A. In
transgenic flies that express the AD-related
genes APP, BACE, and presenilin, A pep-
tides processed from the human APP are
detectable 2 d after eclosion. Most impor-
tantly, the generation of amyloidogenic
A peptides in the retina of transgenic flies
is accompanied by an age-dependent neu-
rodegeneration of the retinal photorecep-
tor cells and the deposition of -amyloid-
like plaque formations that also occur strictly
dependent on aging. The degeneration of
photoreceptor cells preceded the onset of
-amyloid plaque formation, indicating that
-amyloid precursors including A oli-
gomers or protofibrils mediated the toxic
events. Coexpression of FAD presenilin
mutants in UAS-APP and in UAS-APP/
UAS-BACE transgenic flies accelerates
A-induced neurotoxicity in Drosophila.
Age-dependent neurodegeneration and
the onset of plaque deposition are prema-
turely induced in flies with the FAD prese-
nilin mutants, thus resembling the effects
of these mutations in human AD. This
strongly suggests that the expression of
human APP in flies induces analogous bio-
chemical cascades that lead to cellular tox-
icity and degeneration in human AD.
The processing of human APP by BACE
in transgenic flies is dependent on glycosyla-
tion. An interference of post-translational
modifications with APP processing has been
reported previously (Tomita et al., 1998;
Galbete et al., 2000; Georgopoulou et al.,
2001). The processing of human APP in
transgenic flies lacking BACE leads to the
generation of a slightly larger peptide, -A,
by cleavage aminoterminally to the usual
-cleavage site. A similar form of -cleavage
of APP695 at Thr 584 was found previ-
ously in cultured rat neurons (Simons et
al., 1996). However, the responsible
secretase has not been characterized thus
far (Simons et al., 1996).
Both -A and A generated through either - or -cleavage
aggregate to SDS-stable oligomers, suggesting that both cleavage
events generate amyloidogenic products in Drosophila. A oli-
gomers are present in brains of AD patients, and there is growing
evidence that A oligomers are neurotoxic in vivo (Walsh et al.,
2002; Wang et al., 2002; Gong et al., 2003). In human patients
with AD, the density of -amyloid plaques in the brain cortex is
only weakly linked to the severity of dementia, whereas secreted
monomeric and oligomeric forms of Amatch the process of cell
loss and impaired cognitive function more closely (Scheuner et
al., 1996; Lue et al., 1999; McLean et al., 1999; Walsh et al., 2002).
Therefore, the loss of photoreceptor cells in our Drosophila
model could be attributable to toxic effects of the oligomeric
Figure 3. Amyloid-plaque deposition in the retina and neuropil region of transgenic flies expressing the indicated transgenes
in the Drosophila compound eye. A–D, Thioflavin S ( A, B) and 4G8 (C,D) staining of amyloid plaques deposited in the retina of w;
UAS-APP/; UAS-DPsnL235P/gmr-GAL4 transgenic flies ( A, C) and in w; UAS-APP/UAS-BACE; UAS-DPsnL235P/gmr-GAL4 trans-
genic flies ( B, D) from day 37 on. Large amyloid-plaque deposits were more evident in male flies, whereas female flies showed
only small, more scattered, and diffuse thioflavin S-positive staining at 37 d. In w; UAS-BACE/; gmr-GAL4/- and w; gmr-GAL4/
UAS-DPsn-expressing control flies, no plaques could be detected by immunohistochemistry or electron microscopy at each time
point investigated. Arrows indicate amyloid plaques. Scale bars: A, B, 45m; C, D, 50m. E–H, Ultrastructure of amyloid deposits
in the retina of w; UAS-APP/; UAS-DPsnL235P/gmr-GAL4 transgenic flies ( E, G) and in neuropil regions of the optic lobes in w;
UAS-APP/UAS-BACE; UAS-DPsnL235P/gmr-GAL4 transgenic flies ( F, H ). J, Progression of neurodegeneration and thioflavin
S-positive plaque deposition. Dotted lines indicate the presence of thioflavin S-positive plaques and degenerating photoreceptor
cells in10% of the fly heads studied. Filled bars indicate detection of this phenotype in80% of the fly heads studied. Scale
bars: E, F, 15m; G, H, 9m.
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forms of A. Recent findings implicate an involvement of intra-
cellular A accumulation in the pathogenesis of AD disease
(Oddo et al., 2003). Although we have no evidence for intracel-
lular A accumulation in our fly model of Alzheimer’s disease, we
cannot exclude the possibility that intracellular A participates in
the neurodegenerative process in our transgenic fly model.
-amyloid deposits localized outside the retina, despite expres-
sion of the transgenes in photoreceptor cells, suggest A secre-
tion by photoreceptor cells into their projection areas in addition
to local secretion within the retina.
The accelerated degeneration of photoreceptor cells in flies
generating the variant -A peptide may indicate a more toxic
effect of this peptide. Alternatively, it could be related to the
absence of the N-terminal secreted part of APP (APPs) in these
flies, because Western blots did not reveal a -cleaved APP-
ectodomain analogous to APPs. APPs may act as a neuropro-
tective factor (Sisodia and Gallagher, 1998), and the absence of
stable APPs in flies with -cleavage of APP may promote neuro-
toxic effects of -A. In addition, a disruption of axonal transport
mechanisms leading to axonal vesicle stalling may also contribute
to the degenerative phenotypes in flies expressing full length
APP695 (Gunawardena and Goldstein, 2001). However, the ob-
servation that coexpression of an additional copy of FAD prese-
nilin mutants in either combination, UAS-APP or UAS-APP/
UAS-BACE, caused more severe degenerative phenotypes along
with earlier-amyloid plaque deposition supports an A-related
toxicity mechanism.
The reason for the sexual dimorphism observed with respect
to the occurrence of larger and more extensive-amyloid plaques
in male flies as compared with females is unknown but may be
related to the smaller body weight and size of male flies.
Ubiquitous expression of APP, BACE, and DPsn resulted in
semilethality and a visible wing phenotype. This phenotype could
be used to screen for genes, drugs, or metabolites that modulate
APP processing and have the potential to decrease A-induced
cellular degeneration. Both, - and -secretase inhibitor treat-
ment increased the survival rates of the UAS-APP/UAS-BACE/
UAS-DPSn transgenic flies. -secretase cleavage is required not
only for APP processing but also for cleavage of other proteins
such as Notch in vertebrates and invertebrates (Fortini, 2002; De
Strooper, 2003). The -secretase inhibitors available are not spe-
cific for the cleavage of APP. In Drosophila as well as in mice,
loss-of-function mutants of the endogenous PS gene cause em-
bryonic lethal Notch phenotypes (Shen et al., 1997; Ye et al.,
1999). The absence of Notch phenotypes in our experiments in-
dicates that the concentrations of the -secretase inhibitor used
did not lead to a complete inhibition of -secretase cleavage and
allowed sufficient endogenous DPsn activity required for normal
Figure 4. Ectopic veins in wings of transgenic flies expressing APP, BACE, and DPsn ubiqui-
tously under the control of the actin-GAL4 driver. A–C, w; actin-GAL4/; UAS-BACE/UAS-DPsn
transgenic flies presented the normal wing vein pattern ( A), whereas w; actin-GAL4/UAS-APP;
UAS-BACE/ and w; actin-GAL4/UAS-APP; UAS-BACE/UAS-DPsn transgenic flies developed ec-
topic longitudinal and CVs (B, C, arrows). D, Introducing a loss-of-function presenilin allele
( psnC4/) rescued the wing vein phenotype.
Figure 5. Increased median life span of BACE inhibitor-treated flies. Survival curves of w;act-
GAL4/UAS-APP;UAS-BACE/UAS-DPsn and of w;act-GAL4/;UAS-DPsn/ transgenic adult flies
after prolonged treatment with the BACE inhibitor (black triangles and circles, respectively) and
of nontreated flies of the same genotypes (gray triangles and circles, respectively).
Table 1. Ubiquitous expression of APP, BACE, and DPsn as a model system to identify genetic modifiers and
validate pharmacologically active agents
Actin-GAL4 Ratio of flies expected Ratio of flies scored Wing phenotype
(1) UAS-DPsn/ 1:4 (0.25) 1:4 (0.25) Wild type
(2) UAS-BACE/UAS-DPsn 1:4 (0.25) 1:4 (0.25) Wild type
(3) UAS-APP;UAS-BACE/ 1:4 (0.25) 1:40 (0.025) Ectopic veins (75%)
(4) UAS-APP;UAS-BACE/UAS-DPsn 1:4 (0.25) 1:97 (0.01) Ectopic veins (100%)
(5) UAS-APP;UAS-BACE, psnC4/ 1:4 (0.25) 1:13 (0.077) Weak ectopic veins (70%)
(6) UAS-APP 1:4 (0.25) 1:127 (0.008) Wild type
(7) UAS-APPL1;UAS-DPsn/ 1:4 (0.25) 1:4 (0.25) Wild type
Nonsupplemented Vehicle supplemented Inhibitor supplemented Wing phenotype Treatment
(8) UAS-APP;UAS-BACE523/UAS-DPsn 1:17 (0.06) 1:18 (0.06) 1:6 (0.17) Weak ectopic veins (100%) 10 nM BACE inhibitor
(9) UAS-APP;UAS-BACE406/UAS-DPsn 1:100 (0.01) 1:97 (0.01) 1:22 (0.045) Ectopic veins (100%) 100 nM-secretase inhibitor
(10) UAS-DPsn/ 1:2.6 (0.38) 1:3 (0.33) 1:2.7 (0.37) No ectopic veins 10 nM BACE or 100 nM-secretase inhibitor
Ratios of flies expressing the indicated transgenes under the control of the actin-GAL4 driver to nonexpressing flies. A comparison of expected and scored ratios indicates increased lethality during development of the fly. Lethality rate and
wing phenotypes of transgenic flies (lines 1–7) and of transgenic larvae raised on nonsupplemented and vehicle supplemented versus BACE- or-secretase inhibitor supplemented medium (lines 8 –10) are shown.
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development of the fly. However, this inhibition clearly pro-
longed the survival of the transgenic flies as compared with non-
treated flies, suggesting that toxic-amyloid accumulation could
be prevented.
The targeted expression of human disease genes in Drosophila
has been used previously as a model system to study the complex
pathophysiology and potential treatment forms of human neu-
rodegenerative diseases such as Parkinson’s disease and amyotro-
phic lateral sclerosis as well as polyglutamine-repeat diseases
(Feany, 2000; Fortini and Bonini, 2000). Our model closely mim-
ics main characteristics of the human AD neuropathogenesis in
the eye of the fly and demonstrates that A-induced neurodegen-
eration is a conserved principle that acts even in flies. In particu-
lar, this system may be useful in the search of inhibitors of - or
-secretases that are currently regarded as a valid option for the
treatment and prevention of AD.
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